List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10808349/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. Gut, 2022, 71, 391-401.	12.1	21
2	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. Seminars in Cancer Biology, 2022, 84, 129-143.	9.6	41
3	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology, 2022, 84, 242-254.	9.6	22
4	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 251-265.	4.2	22
5	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	1.6	8
6	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	2.8	15
7	Aberrant <scp>DNA</scp> methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the <scp>CpG</scp> island methylator phenotype. International Journal of Cancer, 2022, 150, 617-625.	5.1	3
8	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. Journal of Physical Education and Sports Management, 2022, , mcs.a006156.	1.2	5
9	Subclassification of human hepatic hemangiomas reveals cellular and functional heterogeneity. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
10	Intraepithelial TIRC7+ immune cells are positive prognosticators in cholangiocarcinoma and represent a potential target for immunotherapy. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
11	Non-canonical NF-κB signaling induces proliferation in primary liver cancer. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
12	Direct interaction of the oncogenes YAP and TAZ with the transcription factor HNF1B in hepatocellular carcinoma. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
13	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers, 2022, 14, 1154.	3.7	11
14	Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 139-159.	2.8	28
15	Higher vitamin B6 status is associated with improved survival among patients with stage l–III colorectal cancer. American Journal of Clinical Nutrition, 2022, 116, 303-313.	4.7	2
16	<scp>Homologous recombination deficiency</scp> is inversely correlated with <scp>microsatellite instability</scp> and identifies immunologically cold tumors in most cancer types. Journal of Pathology: Clinical Research, 2022, 8, 371-382.	3.0	10
17	Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review. Current Problems in Cancer, 2022, 46, 100847.	2.0	1
18	N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas. Cancers, 2022, 14, 3091.	3.7	3

#	Article	IF	CITATIONS
19	Multicenter Evaluation of Tissue Classification by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Analytical Chemistry, 2022, 94, 8194-8201.	6.5	12
20	Digital Staging of Hepatic Hemangiomas Reveals Spatial Heterogeneity in Endothelial Cell Composition and Vascular Senescence. Journal of Histochemistry and Cytochemistry, 2022, 70, 531-541.	2.5	1
21	Biobanking in times of crisis – The COVID-19 Autopsy and Biosample Registry Baden-Wuerttemberg. Pathology Research and Practice, 2022, 237, 154011.	2.3	2
22	Diagnosis of digestive system tumours. International Journal of Cancer, 2021, 148, 1040-1050.	5.1	36
23	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	3.2	24
24	Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC. Cancers, 2021, 13, 199.	3.7	8
25	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. Oncolmmunology, 2021, 10, 1860586.	4.6	40
26	Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin. Cell Communication and Signaling, 2021, 19, 15.	6.5	4
27	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	27.8	649
28	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	2.0	8
29	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
30	Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers, 2021, 13, 1682.	3.7	16
31	Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer. Journal of Hepatology, 2021, 74, 1018-1020.	3.7	2
32	Interferonâ€induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Reports, 2021, 22, e49568.	4.5	38
33	Knowledge bases and software support for variant interpretation in precision oncology. Briefings in Bioinformatics, 2021, 22, .	6.5	9
34	SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report. Diagnostic Pathology, 2021, 16, 52.	2.0	6
35	Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 247-255.	2.8	5
36	Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. Cancers, 2021, 13, 3817.	3.7	15

#	Article	IF	CITATIONS
37	Hypoxiaâ€Inducible Factor 1 Alpha–Mediated RelB/APOBEC3B Downâ€regulation Allows Hepatitis B Virus Persistence. Hepatology, 2021, 74, 1766-1781.	7.3	17
38	YAPâ€induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. Liver International, 2021, 41, 3011-3023.	3.9	17
39	Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut, 2021, , gutjnl-2021-325405.	12.1	15
40	MSI testing. Der Pathologe, 2021, 42, 110-118.	1.6	9
41	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 865-878.	3.7	111
42	Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease. Journal of Hepatology, 2021, 75, 810-819.	3.7	34
43	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
44	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer, 2021, 21, 1079.	2.6	14
45	The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. Cancers, 2021, 13, 6272.	3.7	1
46	Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control. Genes Chromosomes and Cancer, 2020, 59, 106-110.	2.8	4
47	The 2019 WHO classification of tumours of the digestive system. Histopathology, 2020, 76, 182-188.	2.9	1,952
48	Testing <i>NTRK</i> testing: Wet″ab and in silico comparison of RNAâ€based targeted sequencing assays. Genes Chromosomes and Cancer, 2020, 59, 178-188.	2.8	52
49	Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium. International Journal of Cancer, 2020, 146, 3256-3266.	5.1	26
50	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	7.3	42
51	Distinct Molecular Phenotype of Sporadic Colorectal Cancers Among Young Patients Based on Multiomics Analysis. Gastroenterology, 2020, 158, 1155-1158.e2.	1.3	42
52	HER2 gene (ERBB2)Âamplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 871-880.	2.8	12
53	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 97-104.	2.5	29
54	Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 460-469.	2.5	16

#	Article	IF	CITATIONS
55	TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Letters, 2020, 473, 164-175.	7.2	39
56	Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death and Disease, 2020, 11, 875.	6.3	17
57	YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis. Cancer Research, 2020, 80, 5502-5514.	0.9	31
58	Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria. Cell Death and Disease, 2020, 11, 1023.	6.3	17
59	<scp>miRNA</scp> profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the <scp>miR</scp> â€451a/ <scp>ATF2</scp> axis. Journal of Pathology, 2020, 252, 239-251.	4.5	18
60	Multi-omics Analysis Reveals Adipose–tumor Crosstalk in Patients with Colorectal Cancer. Cancer Prevention Research, 2020, 13, 817-828.	1.5	19
61	Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Communication and Signaling, 2020, 18, 166.	6.5	21
62	Determining the reliability of liver biopsies in NASH clinical studies. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 653-654.	17.8	11
63	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers, 2020, 12, 2704.	3.7	13
64	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. Journal of Cancer, 2020, 11, 6081-6089.	2.5	8
65	Expanding pancreas donor pool by evaluation of unallocated organs after brain death. Medicine (United States), 2020, 99, e19335.	1.0	0
66	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. Genes Chromosomes and Cancer, 2020, 59, 406-416.	2.8	10
67	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	1.1	81
68	State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials—A Multidisciplinary Approach. Journal of Clinical Oncology, 2020, 38, 1633-1640.	1.6	12
69	Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATAâ€binding protein 3 in nonâ€smallâ€cell lung cancer. Histopathology, 2020, 77, 900-914.	2.9	6
70	NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis. Oncogene, 2020, 39, 3128-3144.	5.9	28
71	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer, 2020, 142, 114-119.	2.0	28
72	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	5.1	14

#	Article	IF	CITATIONS
73	<pre><scp>NTRK</scp> testing: First results of the <scp>QuiPâ€EQA</scp> scheme and a comprehensive map of <scp><i>NTRK</i></scp> fusion variants and their diagnostic coverage by targeted <scp>RNA</scp>â€based <scp>NGS</scp> assays. Genes Chromosomes and Cancer, 2020, 59, 445-453.</pre>	2.8	27
74	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ⁻ve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	1.6	12
75	The Pathology of Severe COVID-19-Related Lung Damage. Deutsches Ärzteblatt International, 2020, 117, 500-506.	0.9	66
76	VaskulÃ r e Erkrankungen und Durchblutungsstörungen. Pathologie, 2020, , 43-62.	0.0	0
77	Propofol-Induced Hepatitis. European Journal of Case Reports in Internal Medicine, 2020, 7, 001921.	0.4	0
78	Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics - Clinical Applications, 2019, 13, e1800035.	1.6	23
79	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin. 2019. 475. 599-608.	2.8	45
80	Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5225-5237.	3.6	21
81	Association between serum IgG level and clinical course in primary sclerosing cholangitis. BMC Gastroenterology, 2019, 19, 153.	2.0	4
82	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	4.2	13
83	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	3.7	32
84	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
85	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1621-1633.	4.2	38
86	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	3.7	36
87	Liver Pathology of Wilson Disease. , 2019, , 139-144.		0
88	Perilipin 1 Expression Differentiates Liposarcoma from Other Types of Soft Tissue Sarcoma. American Journal of Pathology, 2019, 189, 1547-1558.	3.8	13
89	Nucleoporin Nup155 is part of the p53 network in liver cancer. Nature Communications, 2019, 10, 2147.	12.8	29
90	Low frequency of mismatch repair deficiency in gallbladder cancer. Diagnostic Pathology, 2019, 14, 36.	2.0	19

#	Article	IF	CITATIONS
91	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
92	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. Pathology, 2019, 51, 362-368.	0.6	10
93	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. Cell Death and Differentiation, 2019, 26, 2710-2726.	11.2	23
94	Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. Scientific Reports, 2019, 9, 4796.	3.3	29
95	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	5.1	24
96	Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. Scientific Reports, 2019, 9, 4338.	3.3	10
97	YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene, 2019, 38, 5541-5550.	5.9	45
98	Vascular Biomaterial Banking in Academia. European Surgical Research, 2019, 60, 13-23.	1.3	2
99	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. Gastroenterology, 2019, 156, 1190-1205.e14.	1.3	19
100	Emerging Role of the Pathologist in Precision Medicine for HCC. Digestive Diseases and Sciences, 2019, 64, 928-933.	2.3	5
101	Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-10.	1.9	10
102	Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. Cell Communication and Signaling, 2019, 17, 159.	6.5	29
103	HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. BMC Cancer, 2019, 19, 1191.	2.6	15
104	In MALDI–Mass Spectrometry Imaging on Formalinâ€Fixed Paraffinâ€Embedded Tissue Specimen Section Thickness Significantly Influences <i>m/z</i> Peak Intensity. Proteomics - Clinical Applications, 2019, 13, e1800074.	1.6	19
105	Siteâ€toâ€5ite Reproducibility and Spatial Resolution in MALDI–MSI of Peptides from Formalinâ€Fixed Paraffinâ€Embedded Samples. Proteomics - Clinical Applications, 2019, 13, e1800029.	1.6	73
106	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care, 2019, 14, 53-59.	1.4	13
107	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312. 	5.1	95
108	Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. Hepatology, 2019, 69, 2091-2106.	7.3	63

#	Article	IF	CITATIONS
109	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
110	Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. British Journal of Cancer, 2019, 120, 109-114.	6.4	71
111	Identification of MALDI Imaging Proteolytic Peptides Using LCâ€MS/MSâ€Based Biomarker Discovery Data: A Proof of Concept. Proteomics - Clinical Applications, 2019, 13, e1800158.	1.6	17
112	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	5.1	131
113	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes and Cancer, 2019, 58, 3-11.	2.8	14
114	<i>RSPO2</i> gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut, 2019, 68, 1287-1296.	12.1	29
115	Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing. Oncotarget, 2019, 10, 5690-5702.	1.8	15
116	Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage Journal of Clinical Oncology, 2019, 37, 2632-2632.	1.6	4
117	Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. Oncology Letters, 2018, 15, 3586-3593.	1.8	15
118	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	3.7	6,153
119	<i>EML4â€ALK</i> fusion variant V3 is a highâ€risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK ⁺ nonâ€small cell lung cancer. International Journal of Cancer, 2018, 142, 2589-2598.	5.1	93
120	Spatial Tissue Proteomics Quantifies Inter- and Intratumor Heterogeneity in Hepatocellular Carcinoma (HCC). Molecular and Cellular Proteomics, 2018, 17, 810-825.	3.8	65
121	Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology, 2018, 50, 327-332.	0.6	27
122	Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients. Molecular Cancer Research, 2018, 16, 390-402.	3.4	63
123	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	5.2	28
124	Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes and Cancer, 2018, 57, 70-79.	2.8	19
125	Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis. United European Gastroenterology Journal, 2018, 6, 255-262.	3.8	17
126	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Modern Pathology, 2018, 31, 141-149.	5.5	47

#	Article	IF	CITATIONS
127	Interlaboratory concordance of <scp>PD</scp> â€L1 immunohistochemistry for nonâ€smallâ€cell lung cancer. Histopathology, 2018, 72, 449-459.	2.9	71
128	Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut, 2018, 67, 991-993.	12.1	19
129	Proteomics in Pathology. Proteomics, 2018, 18, 1700361.	2.2	18
130	Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology, 2018, 67, 1842-1856.	7.3	48
131	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	3.0	20
132	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	2.8	152
133	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.6	21
134	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Oncolmmunology, 2018, 7, e1526613.	4.6	60
135	Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. Journal of Cancer, 2018, 9, 711-725.	2.5	32
136	The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling. Hepatology, 2018, 68, 1817-1832.	7.3	110
137	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. Gastrointestinal Tumors, 2018, 5, 38-46.	0.7	8
138	Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer, 2018, 18, 616.	2.6	47
139	Molecular dissection of large cell carcinomas of the lung with null immunophenotype. Pathology, 2018, 50, 530-535.	0.6	7
140	Widespread expression of perilipin 5 in normal human tissues and in diseases is restricted to distinct lipid droplet subpopulations. Cell and Tissue Research, 2018, 374, 121-136.	2.9	17
141	Changes in the microarchitecture of the pancreatic cancer stroma are linked to neutrophil-dependent reprogramming of stellate cells and reflected by diffusion-weighted magnetic resonance imaging. Theranostics, 2018, 8, 13-30.	10.0	20
142	The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation. Langenbeck's Archives of Surgery, 2018, 403, 719-731.	1.9	31
143	Distinct Activities of Clycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. EBioMedicine, 2018, 32, 125-133.	6.1	6
144	A field guide for cancer diagnostics using cellâ€free DNA: From principles to practice and clinical applications. Genes Chromosomes and Cancer, 2018, 57, 123-139.	2.8	155

#	Article	IF	CITATIONS
145	Profiling of Oncogenic Signaling in Multiple Myeloma — Association with Biology, Disease Progression and Prognosis. Blood, 2018, 132, 3206-3206.	1.4	1
146	An undifferentiated carcinoma at Klatskin-position with long-term complete remission after chemotherapy. Oncotarget, 2018, 9, 22230-22235.	1.8	2
147	Pancreatic Cancer Surgery. Annals of Surgery, 2017, 265, 565-573.	4.2	258
148	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. OncoImmunology, 2017, 6, e1279777.	4.6	50
149	<scp>DMBT</scp> 1 expression in biliary carcinogenesis with correlation of clinicopathological data. Histopathology, 2017, 70, 1064-1071.	2.9	4
150	The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4. Journal of Hepatology, 2017, 66, 1012-1021.	3.7	102
151	Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology, 2017, 152, 2037-2051.e22.	1.3	118
152	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan ancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes and Cancer, 2017, 56, 651-659.	2.8	35
153	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	5.1	133
154	The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells. Scientific Reports, 2017, 7, 2265.	3.3	51
155	Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin. EMBO Molecular Medicine, 2017, 9, 741-749.	6.9	34
156	Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. American Journal of Pathology, 2017, 187, 228-235.	3.8	26
157	Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer. International Journal of Molecular Medicine, 2017, 40, 1457-1465.	4.0	12
158	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	2.2	76
159	Expression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas. Translational Oncology, 2017, 10, 869-875.	3.7	15
160	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 509-520.	2.8	29
161	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766.	2.8	21
162	Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. Nature Communications, 2017, 8, 1323.	12.8	53

#	Article	IF	CITATIONS
163	EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®). Pathology Research and Practice, 2017, 213, 1530-1535.	2.3	12
164	Mutations in BRCA2 and taxane resistance in prostate cancer. Scientific Reports, 2017, 7, 4574.	3.3	32
165	The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling. Cell Communication and Signaling, 2017, 15, 16.	6.5	16
166	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clinical Sarcoma Research, 2017, 7, 9.	2.3	51
167	Alterations of the nuclear transport system in hepatocellular carcinoma – New basis for therapeutic strategies. Journal of Hepatology, 2017, 67, 1051-1061.	3.7	25
168	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Journal of Physical Education and Sports Management, 2017, 3, a001974.	1.2	54
169	Targeted nextâ€generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes and Cancer, 2017, 56, 255-265.	2.8	21
170	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. Genes Chromosomes and Cancer, 2017, 56, 214-220.	2.8	8
171	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K–AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	2.8	27
172	Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 962-973.	7.0	29
173	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology, 2017, 65, 907-919.	7.3	79
174	Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. BMC Medical Genomics, 2017, 10, 74.	1.5	35
175	MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker. Oncotarget, 2017, 8, 1046-1057.	1.8	26
176	Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. Oncotarget, 2017, 8, 59991-59998.	1.8	15
177	Prognostic relevance of androgen receptor expression in renal cell carcinomas. Oncotarget, 2017, 8, 78545-78555.	1.8	15
178	HER2 testing in gastric cancer diagnosis: Insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany Journal of Clinical Oncology, 2017, 35, 15-15.	1.6	0
179	Clinical Relevance of Different Papillary Growth Patterns of Pulmonary Adenocarcinoma. American Journal of Surgical Pathology, 2016, 40, 818-826.	3.7	24
180	Differential nuclear <scp>ATRX</scp> expression in sarcomas. Histopathology, 2016, 68, 738-745.	2.9	19

#	Article	IF	CITATIONS
181	PI3K/AKT/mTORâ€dependent stabilization of oncogenic farâ€upstream element binding proteins in hepatocellular carcinoma cells. Hepatology, 2016, 63, 813-826.	7.3	52
182	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology, 2016, 29, 1165-1172.	5.5	340
183	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukinâ€6 signaling in hepatocellular carcinoma. Hepatology, 2016, 64, 828-842.	7.3	29
184	Highâ€ŧhroughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes and Cancer, 2016, 55, 30-44.	2.8	65
185	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) – association with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	^S 2.8	80
186	CD14 is associated with biliary stricture formation. Hepatology, 2016, 64, 843-852.	7.3	18
187	HMGB1: The metabolic weapon in the arsenal of NK cells. Molecular and Cellular Oncology, 2016, 3, e1175538.	0.7	12
188	Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood, 2016, 127, 2155-2157.	1.4	52
189	Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. Epigenetics, 2016, 11, 780-790.	2.7	33
190	Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. Molecular and Cellular Proteomics, 2016, 15, 3081-3089.	3.8	72
191	Reply. Journal of the American College of Cardiology, 2016, 68, 2494-2495.	2.8	2
192	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. Diagnostic Pathology, 2016, 11, 133.	2.0	8
193	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer, 2016, 16, 734.	2.6	126
194	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplification. Journal of Physical Education and Sports Management, 2016, 2, a001180.	1.2	57
195	The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nature Communications, 2016, 7, 10764.	12.8	41
196	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncology, The, 2016, 17, 1697-1708.	10.7	532
197	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. Genes Chromosomes and Cancer, 2016, 55, 505-521.	2.8	34
198	Copy number changes of clinically actionable genes in melanoma, nonâ€small cell lung cancer and colorectal cancer—A survey across 822 routine diagnostic cases. Genes Chromosomes and Cancer, 2016, 55, 821-833.	2.8	43

#	Article	IF	CITATIONS
199	Cardiac Amyloid Load. Journal of the American College of Cardiology, 2016, 68, 13-24.	2.8	76
200	Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 313-319.	2.8	60
201	A common genetic variant of <i>fucosyltransferase 2</i> correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European Gastroenterology Journal, 2016, 4, 84-91.	3.8	17
202	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 697-705.	2.8	24
203	2016 ISBER Annual Meeting and Exhibits in Berlin—"Breaking Down Walls: Unifying Biobanking Communities to Secure Our Sustainability― Biopreservation and Biobanking, 2016, 14, 84-86.	1.0	0
204	Individualized medicine and demographic change as determining workload factors in pathology: quo vadis?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 101-108.	2.8	19
205	Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma. European Respiratory Journal, 2016, 47, 938-946.	6.7	69
206	Expression of the apoptosis repressor with caspase recruitment domain (ARC) in liver metastasis of colorectal cancer and its correlation with DNA mismatch repair proteins and p53. Journal of Cancer Research and Clinical Oncology, 2016, 142, 927-935.	2.5	16
207	Methanobactin reverses acute liver failure in a rat model of Wilson disease. Journal of Clinical Investigation, 2016, 126, 2721-2735.	8.2	120
208	Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. Oncotarget, 2016, 7, 28903-28913.	1.8	6
209	The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. Oncotarget, 2016, 7, 418-432.	1.8	28
210	Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget, 2016, 7, 12623-12632.	1.8	68
211	Cellular apoptosis susceptibility (CAS) is linked to integrin \hat{I}^21 and required for tumor cell migration and invasion in hepatocellular carcinoma (HCC). Oncotarget, 2016, 7, 22883-22892.	1.8	18
212	Genetic changes of non-small cell lung cancer under neoadjuvant therapy. Oncotarget, 2016, 7, 29761-29769.	1.8	16
213	Factors influencing BRAFV600 mutation testing quality in melanoma: Results from a large, non-interventional, multicenter study in Germany Journal of Clinical Oncology, 2016, 34, e23142-e23142.	1.6	0
214	Dysregulated serum response factor triggers formation of hepatocellular carcinoma. Hepatology, 2015, 61, 979-989.	7.3	30
215	Hepatic stellate cellâ€expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. EMBO Molecular Medicine, 2015, 7, 332-338	6.9	58
216	<scp>SRC</scp> inhibition represents a potential therapeutic strategy in liposarcoma. International Journal of Cancer, 2015, 137, 2578-2588.	5.1	18

#	Article	IF	CITATIONS
217	Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma. American Journal of Surgical Pathology, 2015, 39, 793-801.	3.7	206
218	Concomitant expression of far upstream element (<i><scp>FUSE</scp></i>) binding protein (<i><scp>FBP</scp></i>) interacting repressor (<scp>FIR</scp>) and its splice variants induce migration and invasion of nonâ€small cell lung cancer (<scp>NSCLC</scp>) cells. Journal of Pathology, 2015, 237, 390-401.	4.5	32
219	<scp>PBRM1</scp> (<scp>BAF180</scp>) protein is functionally regulated by p53â€induced protein degradation in renal cell carcinomas. Journal of Pathology, 2015, 237, 460-471.	4.5	18
220	Aggressive systemic mastocytosis of the liver with cholangitis. Hepatic Oncology, 2015, 2, 343-347.	4.2	0
221	Semiconductorâ€Based Sequencing of Formalinâ€Fixed, Paraffinâ€Embedded Colorectal Cancer Samples. Oncologist, 2015, 20, e10-1.	3.7	10
222	NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis. Cancer Cell, 2015, 28, 582-598.	16.8	98
223	Outcome after a liver resection of benign lesions. Hpb, 2015, 17, 994-1000.	0.3	17
224	Protumorigenic role of Timeless in hepatocellular carcinoma. International Journal of Oncology, 2015, 46, 597-606.	3.3	32
225	Liver cancer biopsy – back to the future?!. Hepatology, 2015, 61, 431-433.	7.3	58
226	DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Modern Pathology, 2015, 28, 822-829.	5.5	142
227	Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study. American Journal of Clinical Nutrition, 2015, 102, 433-443.	4.7	113
228	<i>EGFR</i> Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1254-1261.	2.5	38
229	Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2015, 13, 2372-2379.	4.4	21
230	Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 638-644.	1.1	83
231	Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. Journal of Hepatology, 2015, 63, 829-837.	3.7	47
232	A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Letters, 2015, 369, 396-404.	7.2	29
233	Hepatobiliary malignancies in Wilson disease. Liver International, 2015, 35, 1615-1622.	3.9	78
234	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. British Journal of Cancer, 2015, 113, 1343-1349.	6.4	54

#	Article	IF	CITATIONS
235	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. Lung Cancer, 2015, 90, 465-471.	2.0	36
236	Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. Modern Pathology, 2015, 28, 523-532.	5.5	36
237	Chronic liver inflammation and hepatocellular carcinogenesis are independent of <scp>S</scp> 100 <scp>A</scp> 9. International Journal of Cancer, 2015, 136, 2458-2463.	5.1	9
238	<i>GHSR</i> DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers. Oncotarget, 2015, 6, 4418-4427.	1.8	25
239	Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Hepatobiliary Surgery and Nutrition, 2015, 4, 426-35.	1.5	6
240	An Inducible Hepatocellular Carcinoma Model for Preclinical Evaluation of Antiangiogenic Therapy in Adult Mice. Cancer Research, 2014, 74, 4157-4169.	0.9	23
241	Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 661-672.	2.8	61
242	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. European Respiratory Journal, 2014, 43, 872-883.	6.7	97
243	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Modern Pathology, 2014, 27, 1028-1034.	5.5	96
244	<scp><i>PNPLA3</i></scp> in endâ€stage liver disease: Alcohol consumption, hepatocellular carcinoma development, and transplantationâ€free survival. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1477-1484.	2.8	39
245	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology, 2014, 59, 1900-1911.	7.3	155
246	EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology, 2014, 59, 1886-1899.	7.3	74
247	Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology, 2014, 60, 1241-1250.	7.3	39
248	Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology, 2014, 59, 544-554.	7.3	97
249	Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria. Journal of Thoracic Oncology, 2014, 9, 1685-1692.	1.1	66
250	Multicenter ALK Testing in Non–Small-Cell Lung Cancer: Results of a Round Robin Test. Journal of Thoracic Oncology, 2014, 9, 1464-1469.	1.1	17
251	Human and Mouse <i>VEGFA</i> -Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment. Cancer Discovery, 2014, 4, 730-743.	9.4	165
252	<i><scp>ROS</scp>1</i> expression and translocations in nonâ€smallâ€cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology, 2014, 65, 187-194.	2.9	96

#	Article	IF	CITATIONS
253	Nuclear relocation of <scp>STAT</scp> 6 reliably predicts <i>NAB2</i> – <i>STAT6</i> fusion for the diagnosis of solitary fibrous tumour. Histopathology, 2014, 65, 613-622.	2.9	101
254	Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. European Journal of Radiology, 2014, 83, 970-974.	2.6	11
255	Prosurvival function of the cellular apoptosis susceptibility/importin-α1 transport cycle is repressed by p53 in liver cancer. Hepatology, 2014, 60, 884-895.	7.3	29
256	Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. Surgery, 2014, 155, 245-254.	1.9	33
257	Participation in and support of clinical studies and other scientific investigations – Statement of the German Society for Pathology. Pathology Research and Practice, 2014, 210, 705-712.	2.3	3
258	Comparison of molecular abnormalities in vulvar and vaginal melanomas. Modern Pathology, 2014, 27, 1386-1393.	5.5	70
259	KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE). Diagnostic Pathology, 2014, 9, 116.	2.0	12
260	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	30.7	242
261	Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Medicine, 2014, 6, 34.	8.2	34
262	Efficacy and Nontarget Effects of Transarterial Chemoembolization in Bridging of Hepatocellular Carcinoma Patients to Liver Transplantation: A Histopathologic Study. Journal of Vascular and Interventional Radiology, 2014, 25, 1018-1026.e4.	0.5	17
263	Perilipin discerns chronic from acute hepatocellular steatosis. Journal of Hepatology, 2014, 60, 633-642.	3.7	76
264	Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathology Research and Practice, 2014, 210, 83-91.	2.3	9
265	Molecular analysis of pancreatic acinar cell cystadenomas: Evidence of a non-neoplastic nature. Oncology Letters, 2014, 8, 852-858.	1.8	26
266	Signaling Pathway Profiling in Multiple Myeloma. Blood, 2014, 124, 644-644.	1.4	1
267	Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiation Oncology, 2013, 8, 27.	2.7	46
268	Adipophilin/perilipinâ€2 as a lipid dropletâ€specific marker for metabolically active cells and diseases associated with metabolic dysregulation. Histopathology, 2013, 62, 617-631.	2.9	98
269	Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach. Journal of Molecular Diagnostics, 2013, 15, 765-775.	2.8	107
270	Obesity Promotes Liver Carcinogenesis via Mcl-1 Stabilization Independent of IL-6Rα Signaling. Cell Reports, 2013, 4, 669-680.	6.4	30

#	Article	IF	CITATIONS
271	Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer, 2013, 13, 532.	2.6	23
272	Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss. Modern Pathology, 2013, 26, 1161-1171.	5.5	47
273	Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clinical Transplantation, 2013, 27, 914-922.	1.6	56
274	Posttranscriptional destabilization of the liver-specific long noncoding RNA <i>HULC</i> by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology, 2013, 58, 1703-1712.	7.3	208
275	FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology, 2013, 59, 1278-1284.	3.7	74
276	Large lymphatic vessel density in primary malignant melanoma predicts sentinel node status. Journal of the American Academy of Dermatology, 2013, 69, 827-828.	1.2	2
277	Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma. Gastroenterology, 2013, 144, 1530-1542.e12.	1.3	278
278	A Direct InÂVivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration. Cell, 2013, 153, 389-401.	28.9	127
279	Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilinâ€2 expression in periâ€tumourous liver correlates with increased survival. Liver International, 2013, 33, 1428-1440.	3.9	49
280	Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing. Lung Cancer, 2013, 81, 200-206.	2.0	48
281	Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunology, Immunotherapy, 2013, 62, 1453-1461.	4.2	155
282	Differential Expression of the Tumor Suppressor A-Kinase Anchor Protein 12 in Human Diffuse and Pilocytic Astrocytomas Is Regulated by Promoter Methylation. Journal of Neuropathology and Experimental Neurology, 2013, 72, 933-941.	1.7	11
283	SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells. Cancer Research, 2013, 73, 2518-2528.	0.9	62
284	Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discovery, 2013, 3, 862-869.	9.4	202
285	Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biology, 2013, 14, r137.	9.6	78
286	Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma. Oncology Reports, 2013, 30, 2245-2253.	2.6	18
287	Mutation analysis in malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 2-10.	0.8	2
288	Mutationsanalysen im malignen Melanom. JDDG - Journal of the German Society of Dermatology, 2013, 11, 2-11.	0.8	11

#	Article	IF	CITATIONS
289	Erythropoietin Combined with ACE Inhibitor Prevents Heart Remodeling in 5/6 Nephrectomized Rats Independently of Blood Pressure and Kidney Function. American Journal of Nephrology, 2013, 38, 124-135.	3.1	26
290	A Frequent PNPLA3 Variant Is a Sex Specific Disease Modifier in PSC Patients with Bile Duct Stenosis. PLoS ONE, 2013, 8, e58734.	2.5	28
291	Stathmin Regulates Keratinocyte Proliferation and Migration during Cutaneous Regeneration. PLoS ONE, 2013, 8, e75075.	2.5	16
292	Molecular Pathology of Liver Tumors. , 2013, , 43-63.		3
293	A Systems Biology Study on NFκB Signaling in Primary Mouse Hepatocytes. Frontiers in Physiology, 2012, 3, 466.	2.8	9
294	Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. European Respiratory Journal, 2012, 39, 1437-1442.	6.7	92
295	Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Modern Pathology, 2012, 25, 308-315.	5.5	102
296	The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Modern Pathology, 2012, 25, 911-916.	5.5	49
297	Loss of the abundant nuclear non-coding RNA <i>MALAT1</i> is compatible with life and development. RNA Biology, 2012, 9, 1076-1087.	3.1	355
298	Systemic Mastocytosis: A Rare Case of Increased Liver Stiffness. Case Reports in Hepatology, 2012, 2012, 1-6.	0.7	11
299	A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK. Journal of Thoracic Oncology, 2012, 7, 1198-1199.	1.1	32
300	Transitions Between Flat Epithelial Atypia and Low-grade Ductal Carcinoma In Situ of the Breast. American Journal of Surgical Pathology, 2012, 36, 1247-1252.	3.7	13
301	Largeâ€scale comparative analyses of immunomarkers for diagnostic subtyping of nonâ€smallâ€cell lung cancer biopsies. Histopathology, 2012, 61, 1017-1025.	2.9	102
302	The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. Journal of Clinical Oncology, 2012, 30, 1438-1446.	1.6	606
303	Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncology, The, 2012, 13, 598-606.	10.7	147
304	Polymorphonuclear neutrophils promote dyshesion of tumor cells and elastaseâ€mediated degradation of <scp>E</scp> â€cadherin in pancreatic tumors. European Journal of Immunology, 2012, 42, 3369-3380.	2.9	69
305	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology, 2012, 56, 1817-1827.	7.3	136
306	Nuclear Pore Component Nup98 Is a Potential Tumor Suppressor and Regulates Posttranscriptional Expression of Select p53 Target Genes. Molecular Cell, 2012, 48, 799-810.	9.7	57

#	Article	IF	CITATIONS
307	Genomeâ€wide methylation screen in lowâ€grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB Journal, 2012, 26, 4937-4950.	0.5	84
308	Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Endocrine-Related Cancer, 2012, 19, 217-232.	3.1	15
309	Transcriptional regulators in hepatocarcinogenesis – Key integrators of malignant transformation. Journal of Hepatology, 2012, 57, 186-195.	3.7	20
310	Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine, 2012, 57, 46-53.	3.2	73
311	Disruption of Trp53 in Livers of Mice Induces Formation of Carcinomas With Bilineal Differentiation. Gastroenterology, 2012, 142, 1229-1239.e3.	1.3	74
312	Persistence of HCV in Quiescent Hepatic Cells Under Conditions of an Interferon-Induced Antiviral Response. Gastroenterology, 2012, 143, 429-438.e8.	1.3	41
313	S100A9 is a Biliary Protein Marker of Disease Activity in Primary Sclerosing Cholangitis. PLoS ONE, 2012, 7, e29821.	2.5	29
314	Unique Cell Type-Specific Junctional Complexes in Vascular Endothelium of Human and Rat Liver Sinusoids. PLoS ONE, 2012, 7, e34206.	2.5	54
315	Nuclear accumulation of seven in absentia homologueâ€2 supports motility and proliferation of liver cancer cells. International Journal of Cancer, 2012, 131, 2016-2026.	5.1	21
316	Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Clinical and Experimental Metastasis, 2012, 29, 409-417.	3.3	24
317	Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 299-308.	2.8	60
318	Decentral gene expression analysis for ER+/Her2â^' breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 251-259.	2.8	88
319	Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 407-414.	2.8	64
320	Iron metabolism and the role of <scp>HFE</scp> gene polymorphisms in <scp>W</scp> ilson disease. Liver International, 2012, 32, 165-170.	3.9	38
321	Oncogenetic tree modeling of human hepatocarcinogenesis. International Journal of Cancer, 2012, 130, 575-583.	5.1	29
322	MHC class II expression in pancreatic tumors: a link to intratumoral inflammation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 47-60.	2.8	17
323	Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 2011, 479, 547-551.	27.8	1,208
324	Recruitment and Activation of a Lipid Kinase by Hepatitis C Virus NS5A Is Essential for Integrity of the Membranous Replication Compartment. Cell Host and Microbe, 2011, 9, 32-45.	11.0	435

#	Article	IF	CITATIONS
325	Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Letters, 2011, 301, 203-211.	7.2	18
326	Discovered on gastrointestinal stromal tumor 1 (DOG1) is expressed in pancreatic centroacinar cells and in solid-pseudopapillary neoplasms—novel evidence for a histogenetic relationship. Human Pathology, 2011, 42, 817-823.	2.0	41
327	Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells. Journal of Hepatology, 2011, 55, 1049-1057.	3.7	52
328	EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 95-98.	2.8	86
329	Letter to the editor—reply to comments of Carter et al Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 249-250.	2.8	2
330	Strategies for hepatocellular carcinoma therapy and diagnostics: Lessons learned from high throughput and profiling approaches. Hepatology, 2011, 53, 2112-2121.	7.3	49
331	Liver specific overexpression of plateletâ€derived growth factorâ€B accelerates liver cancer development in chemically induced liver carcinogenesis. International Journal of Cancer, 2011, 128, 1259-1268.	5.1	59
332	Phosphatidylinositolâ€3′â€kinase/AKT signaling is essential in synovial sarcoma. International Journal of Cancer, 2011, 129, 1564-1575.	5.1	47
333	Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathology Research and Practice, 2011, 207, 8-14.	2.3	33
334	Heat Shock Protein 90-Sheltered Overexpression of Insulin-Like Growth Factor 1 Receptor Contributes to Malignancy of Thymic Epithelial Tumors. Clinical Cancer Research, 2011, 17, 2237-2249.	7.0	27
335	E–N-cadherin heterodimers define novel adherens junctions connecting endoderm-derived cells. Journal of Cell Biology, 2011, 195, 873-887.	5.2	51
336	Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. Modern Pathology, 2011, 24, 564-570.	5.5	51
337	Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines. Clinical Cancer Research, 2011, 17, 678-689.	7.0	250
338	Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome. Journal of Clinical Oncology, 2011, 29, 223-227.	1.6	46
339	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. Cancer Research, 2011, 71, 5670-5677.	0.9	369
340	Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. Journal of Clinical Investigation, 2011, 121, 703-714.	8.2	133
341	Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation. Molecular Carcinogenesis, 2010, 49, 175-182.	2.7	25
342	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 2010, 5, 1706-1713.	1.1	273

#	Article	IF	CITATIONS
343	Small bowel adenocarcinomas in celiac disease follow the CIM-MSI pathway. Oncology Reports, 2010, 24, 1535-9.	2.6	25
344	Liver Resection for Multimodal Treatment of Breast Cancer Metastases: Identification of Prognostic Factors. Annals of Surgical Oncology, 2010, 17, 1546-1554.	1.5	91
345	Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 277-285.	2.8	42
346	The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 449-454.	2.8	79
347	Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 741-747.	2.8	31
348	Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer, 2010, 10, 524.	2.6	130
349	Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology, 2010, 51, NA-NA.	7.3	139
350	Down-regulation of tumor suppressor a kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms. Hepatology, 2010, 52, 2023-2033.	7.3	61
351	Expression of L1CAM, COXâ€2, EGFR, câ€KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?. Histopathology, 2010, 56, 440-448.	2.9	28
352	Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. Journal of Experimental Medicine, 2010, 207, 1617-1624.	8.5	286
353	Pathology and Biopsy Assessment of Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2010, 28, 197-202.	1.9	52
354	Danger Signaling Protein HMGB1 Induces a Distinct Form of Cell Death Accompanied by Formation of Giant Mitochondria. Cancer Research, 2010, 70, 8558-8568.	0.9	51
355	Lipid droplet-associated PAT-proteins show frequent and differential expression in neoplastic steatogenesis. Modern Pathology, 2010, 23, 480-492.	5.5	131
356	The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. Journal of Clinical Investigation, 2010, 120, 3820-3833.	8.2	45
357	Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis. World Journal of Gastroenterology, 2010, 16, 966.	3.3	201
358	Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. Journal of Cell Biology, 2010, 190, i2-i2.	5.2	1
359	Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. , 2010, 32, 333-40.		18
360	Estimation of Immune Cell Densities in Immune Cell Conglomerates: An Approach for High-Throughput Quantification. PLoS ONE, 2009, 4, e7847.	2.5	29

#	Article	IF	CITATIONS
361	Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Experimental and Molecular Medicine, 2009, 41, 349.	7.7	26
362	Expression Pattern and Functional Relevance of Epidermal Growth Factor Receptor and Cyclooxygenase-2: Novel Chemotherapeutic Targets in Pancreatic Endocrine Tumors?. American Journal of Gastroenterology, 2009, 104, 171-181.	0.4	39
363	Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. Clinical Cancer Research, 2009, 15, 650-659.	7.0	59
364	Invasive Tubular Carcinoma of the Breast Frequently is Clonally Related to Flat Epithelial Atypia and Low-grade Ductal Carcinoma In Situ. American Journal of Surgical Pathology, 2009, 33, 1646-1653.	3.7	48
365	Arterial calcification in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 2488-2496.	0.7	62
366	Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non–Small Cell Lung Cancer. Cancer Research, 2009, 69, 2234-2243.	0.9	85
367	Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology, 2009, 50, 102-112.	7.3	68
368	Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology, 2009, 50, 1130-1139.	7.3	92
369	S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology, 2009, 50, 1251-1262.	7.3	129
370	DMBT1 functions as patternâ€recognition molecule for polyâ€sulfated and polyâ€phosphorylated ligands. European Journal of Immunology, 2009, 39, 833-842.	2.9	58
371	Transcriptional activation of the βâ€ <i>catenin</i> gene at the invasion front of colorectal liver metastases. Journal of Pathology, 2009, 218, 370-379.	4.5	55
372	AP-1-Controlled Hepatocyte Growth Factor Activation Promotes Keratinocyte Migration via CEACAM1 and Urokinase Plasminogen Activator/Urokinase Plasminogen Receptor. Journal of Investigative Dermatology, 2009, 129, 1140-1148.	0.7	17
373	Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Laboratory Investigation, 2009, 89, 520-530.	3.7	34
374	p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nature Genetics, 2009, 41, 1138-1143.	21.4	96
375	A new link between cancer and inflammation?. Journal of Hepatology, 2009, 51, 230-232.	3.7	4
376	Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology, 2008, 47, 511-520.	7.3	173
377	MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 2008, 47, 1223-1232.	7.3	384
378	Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Research and Treatment, 2008, 107, 331-335.	2.5	50

#	Article	IF	CITATIONS
379	Secondary sclerosing cholangitis after intensive care unit treatment: clues to the histopathological differential diagnosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 339-345.	2.8	44
380	Differential expression of Eâ€prostanoid receptors in human hepatocellular carcinoma. International Journal of Cancer, 2008, 122, 547-557.	5.1	22
381	Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. International Journal of Cancer, 2008, 122, 2719-2725.	5.1	41
382	Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. Genes Chromosomes and Cancer, 2008, 47, 159-164.	2.8	9
383	Differential pattern of lipid droplet-associated proteins and <i>de novo</i> perilipin expression in hepatocyte steatogenesis. Hepatology, 2008, 47, 1936-1946.	7.3	221
384	Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology, 2008, 48, 146-156.	7.3	100
385	A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology, 2008, 48, 1157-1166.	7.3	109
386	Most Pancreatic Cancer Resections are R1 Resections. Annals of Surgical Oncology, 2008, 15, 1651-1660.	1.5	574
387	Cross-species comparison of biological themes and underlying genes on a global gene expression scale in a mouse model of colorectal liver metastasis and in clinical specimens. BMC Genomics, 2008, 9, 448.	2.8	6
388	Ampullary adenocarcinoma $\hat{a} \in $ differentiation matters. BMC Cancer, 2008, 8, 251.	2.6	29
389	Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene, 2008, 423, 23-28.	2.2	52
390	An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer. Cell, 2008, 135, 852-864.	28.9	404
391	Decoy Receptor 3 Is a Prognostic Factor in Renal Cell Cancer. Neoplasia, 2008, 10, 1049-IN2.	5.3	59
392	Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1297-1302.	7.1	101
392 393	Hepatic NF-Î [®] B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1297-1302. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 196-204.	7.1 3.0	101 46
392 393 394	Hepatic NF-Î [®] B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1297-1302. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 196-204. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1690.	7.1 3.0 3.3	101 46 67
392 393 394 395	Hepatic NF-ΰB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1297-1302. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 196-204. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1690. Comparative pathology. , 2008, , 47-73.	7.1 3.0 3.3	101 46 67 0

#	Article	IF	CITATIONS
397	Cyclooxygenase-2 (COX-2) - A Therapeutic Target in Liver Cancer?. Current Pharmaceutical Design, 2007, 13, 3305-3315.	1.9	44
398	Induction of Apoptosis by Celecoxib in Cell Culture: An Uncertain Role for Cyclooxygenase-2. Cancer Research, 2007, 67, 5576.1-5576.	0.9	0
399	Calcification of Coronary Intima and Media. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 121-134.	4.5	127
400	Hypothetical Progression Model of Pancreatic Cancer With Origin in the Centroacinar-Acinar Compartment. Pancreas, 2007, 35, 212-217.	1.1	62
401	Early Undifferentiated Pancreatic Carcinoma With Osteoclastlike Giant Cells: Direct Evidence for Ductal Evolution. American Journal of Surgical Pathology, 2007, 31, 1919-1925.	3.7	43
402	Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Letters, 2007, 248, 186-191.	7.2	51
403	Exonuclease-1 Deletion Impairs DNA Damage Signaling and Prolongs Lifespan of Telomere-Dysfunctional Mice. Cell, 2007, 130, 863-877.	28.9	139
404	Telomerase Deletion Limits Progression of p53-Mutant Hepatocellular Carcinoma With Short Telomeres in Chronic Liver Disease. Gastroenterology, 2007, 132, 1465-1475.	1.3	59
405	DMBT1 Confers Mucosal Protection In Vivo and a Deletion Variant Is Associated With Crohn's Disease. Gastroenterology, 2007, 133, 1499-1509.	1.3	96
406	Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology, 2007, 46, 759-768.	7.3	103
407	Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nature Genetics, 2007, 39, 99-105.	21.4	399
408	Novel Type I Hair Keratins K39 and K40 Are the Last to be Expressed in Differentiation of the Hair: Completion of the Human Hair Keratin Catalog. Journal of Investigative Dermatology, 2007, 127, 1532-1535.	0.7	55
409	Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathology and Oncology Research, 2007, 13, 84-90.	1.9	18
410	Pancreatic cancer — Pathology. Chinese-German Journal of Clinical Oncology, 2007, 6, 95-101.	0.1	1
411	Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. Journal of Hepatology, 2006, 45, 419-428.	3.7	209
412	Ex vivo analysis of antineoplastic agents in precision-cut tissue slices of human origin: effects of cyclooxygenase-2 inhibition in hepatocellular carcinoma. Liver International, 2006, 26, 604-612.	3.9	23
413	K25 (K25irs1), K26 (K25irs2), K27 (K25irs3), and K28 (K25irs4) Represent the Type I Inner Root Sheath Keratins of the Human Hair Follicle. Journal of Investigative Dermatology, 2006, 126, 2377-2386.	0.7	70
414	Granulocyte–Macrophage Colony-Stimulating Factor Is Essential for Normal Wound Healing. Journal of Investigative Dermatology Symposium Proceedings, 2006, 11, 87-92.	0.8	45

#	Article	IF	CITATIONS
415	COX-2 upregulation in thymomas and thymic carcinomas. International Journal of Cancer, 2006, 119, 2063-2070.	5.1	16
416	The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment. Current Cancer Therapy Reviews, 2006, 2, 157-167.	0.3	5
417	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 7059-7066.	0.9	151
418	Nucleoporin 88 expression in hepatitis B and C virus-related liver diseases. World Journal of Gastroenterology, 2006, 12, 5870.	3.3	17
419	Chromosomal imbalances in sporadic neuroendocrine tumours of the thymus. Cancer Letters, 2005, 223, 169-174.	7.2	20
420	Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 2004, 25, 1193-1199.	2.8	75
421	Factors of transforming growth factor ? signalling are co-regulated in human hepatocellular carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 589-596.	2.8	29
422	Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Letters, 2004, 206, 85-96.	7.2	47
423	Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression. Cancer Research, 2004, 64, 6058-6064.	0.9	119
424	Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. Journal of Pathology, 2003, 201, 250-259.	4.5	107
425	Overexpression of Human Dickkopf-1, an Antagonist of wingless/WNT Signaling, in Human Hepatoblastomas and Wilms' Tumors. Laboratory Investigation, 2003, 83, 429-434.	3.7	134
426	Molecular pathogenesis of human hepatocellular carcinoma. Advances in Cancer Research, 2002, 86, 67-112.	5.0	48
427	Autoimmune hepatitis and overlap syndromes. Clinics in Liver Disease, 2002, 6, 349-362.	2.1	55
428	Serum versus intrahepatic HCV RNA and liver histology. Hepatology, 2002, 35, 1552-1553.	7.3	2
429	Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 2002, 36, 885-894.	7.3	143
430	Resistance of keratinocytes to TGFβ-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. Journal of Cell Science, 2002, 115, 2189-2198.	2.0	113
431	Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. Journal of Cell Science, 2002, 115, 2189-98.	2.0	88
432	CONCENTRATIONS OF HEPATOCYTE GROWTH FACTOR IN CEREBROSPINAL FLUID UNDER NORMAL AND DIFFERENT PATHOLOGICAL CONDITIONS. Cytokine, 2001, 14, 170-176.	3.2	22

#	Article	IF	CITATIONS
433	AMYOTROPHIC LATERAL SCLEROSIS: EVIDENCE FOR INTACT HEPATOCYTE GROWTH FACTOR/MET SIGNALLING AXIS. Cytokine, 2001, 15, 315-319.	3.2	6
434	T cell receptor Vβ chain restriction and preferred CDR3 motifs of liver-kidney microsomal antigen (LKM-1)-reactive T cells from autoimmune hepatitis patients. Liver, 2001, 21, 18-25.	0.1	20
435	Keratinocyte-Derived Granulocyte-Macrophage Colony Stimulating Factor Accelerates Wound Healing: Stimulation of Keratinocyte Proliferation, Granulation Tissue Formation, and Vascularization. Journal of Investigative Dermatology, 2001, 117, 1382-1390.	0.7	142
436	The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells. Oncogene, 2001, 20, 972-979.	5.9	27
437	Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene, 2001, 20, 5015-5024.	5.9	68
438	Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene, 2001, 20, 7761-7769.	5.9	45
439	Interleukin-6 and the soluble interleukin-6 receptor induce stem cell factor and Flt-3L expression in vivo and in vitro. Experimental Hematology, 2001, 29, 146-155.	0.4	20
440	Expression of câ€Met in developing rat hippocampus: evidence for HGF as a neurotrophic factor for calbindin Dâ€expressing neurons. European Journal of Neuroscience, 2000, 12, 3453-3461.	2.6	58
441	Heterozygosity for the hemochromatosis gene in liver diseases - prevalence and effects on liver histology. Liver International, 2000, 20, 482-486.	3.9	37
442	Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology, 2000, 119, 1663-1671.	1.3	115
443	TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. American Journal of Physiology - Renal Physiology, 1999, 276, G1059-G1068.	3.4	120
444	Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors. Journal of Molecular Medicine, 1999, 77, 505-510.	3.9	52
445	Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology, 1999, 29, 223-229.	7.3	66
446	Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. International Journal of Cancer, 1999, 80, 497-505.	5.1	88
447	De novo expression of nonhepatocellular cytokeratins in Mallory body formation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 432, 143-152.	2.8	17
448	Induction of Bone Morphogenetic Protein-6 in Skin Wounds. Delayed Reepitheliazation and Scar Formation in BMP-6 Overexpressing Transgenic Mice. Journal of Investigative Dermatology, 1998, 111, 1145-1152.	0.7	54
449	Nonparenchymal cells in chronically hyperinsulinemic liver acini of diabetic rats, with special regard to hepatic stellate cells. Journal of Hepatology, 1998, 28, 709-716.	3.7	2
450	Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extramedullary Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mice. American Journal of Pathology, 1998, 153, 639-648.	3.8	86

#	Article	IF	CITATIONS
451	Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6–sIL-6R Double Transgenic Mice. Journal of Experimental Medicine, 1997, 185, 755-766.	8.5	167
452	Establishment and Characterization of a Nontumorigenic Cell Line Derived from a Human Hepatocellular Adenoma Expressing Hepatocyte-Specific Markers. Experimental Cell Research, 1997, 236, 418-426.	2.6	12
453	Neoexpression of the c-met/Hepatocyte Growth Factor-Scatter Factor Receptor Gene in Activated Monocytes. Blood, 1997, 90, 4450-4458.	1.4	72
454	Neoexpression of the c-met/Hepatocyte Growth Factor-Scatter Factor Receptor Gene in Activated Monocytes. Blood, 1997, 90, 4450-4458.	1.4	3
455	Intracellular accumulation of incompletely processed transforming growth factor-alpha polypeptides in ground glass hepatocytes of chronic hepatitis B virus infection. Journal of Hepatology, 1996, 24, 547-554.	3.7	7
456	Current pathogenetic and molecular concepts in viral liver carcinogenesis. Vigiliae Christianae, 1993, 63, 71-89.	0.1	42
457	Hepatocyte growth factor/hepatopoietin A is expressed in fat-storing cells from rat liver but not	7.3	212